Atea Pharmaceuticals, INC Form 4 insider transactions

Director Bruno Lucidi reports acquisition of stock options and restricted stock units in Atea Pharmaceuticals, Inc.

Director Bruce Polsky sold 17,544 shares of Atea Pharmaceuticals to cover taxes upon vesting of restricted stock units and was granted stock options and restricted stock units.

Director Polly A. Murphy reported the acquisition of stock options and restricted stock units in Atea Pharmaceuticals on June 21, 2024.

Director Polly A. Murphy reports a transaction involving Atea Pharmaceuticals' common stock and restricted stock units.

Director Bruno Lucidi reports the conversion of restricted stock units into common stock of Atea Pharmaceuticals.

Director Franklin M. Berger reports the conversion of restricted stock units into common stock of Atea Pharmaceuticals.

Director Bruce Polsky reports a transaction involving Atea Pharmaceuticals' common stock and restricted stock units.

Director Barbara Gayle Duncan reports the conversion of restricted stock units into common stock of Atea Pharmaceuticals.

Director Jerome M. Adams reports the conversion of restricted stock units into common stock of Atea Pharmaceuticals.

Jean-Pierre Sommadossi, President, CEO, and Chairman of Atea Pharmaceuticals, Inc., sold 1,006 shares of common stock on June 5, 2024.